Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study

Neurology and Therapy

Volumn 5, Issue 1, 2016, Pages 85-99

  Foppa, Aline Aparecida ^a   Chemello, Clarice ^b   Vargas Peláez, Claudia Marcela ^a   Farias, Mareni Rocha ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Medication therapy management; Parkinson disease; Pharmaceutical care

Indexed keywords

ADULT; ARTICLE; COMMUNITY ASSESSMENT; CONSTIPATION; DYSPHAGIA; EVALUATION AND FOLLOW UP; FEMALE; HEALTH PRACTITIONER; HUMAN; HYPOTENSION; INTERVENTION STUDY; INTERVIEW; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROLOGIC DISEASE; PARKINSON DISEASE; PARKINSON DISEASE QUESTIONNAIRE; PHARMACIST; PRIORITY JOURNAL; PSYCHOLOGICAL WELLBEING ASSESSMENT; QUALITY OF LIFE ASSESSMENT; QUASI EXPERIMENTAL STUDY; QUESTIONNAIRE;

EID: 85006200884     PISSN: 21938253     EISSN: 21936536     Source Type: Journal    
DOI: 10.1007/s40120-016-0046-4     Document Type: Article

References (55)

1. Prediger RD, Bortolanza M, Issy CCA, Dos Santos BL, Bel ED, Vozari RR. Dopaminergic neurons in Parkinson’s disease. In: Kostrzewa R, editor. Handobook of neurotoxicity. New York: Springer; 2013. p. 01–36.
2. Carod-Artal FJ, Vargas AP, Martinez-Martin P. Determinants of quality of life in Brazilian patients with Parkinson’s disease. Mov Disord. 2007;22(10):1408–15.
3. Marinus J, Ramaker C, Van Hilten JJ, Stiggelbout AM. Health related quality of life in Parkinson’s disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry. 2002;72(2):241–8.
4. Camargos ACR, Cópio FCQ, Sousa TRR, Goulart F. O impacto da doença de Parkinson na qualidade de vida: uma revisão de literatura. Revista Brasileira de Fisioterapia. 2004;8(3):267–72.
5. Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA. Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson’s disease. Mov Disord. 2008;23(3):359–65.
6. Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson’s disease: evidence from administrative claims data. Mov Disord. 2010;25(4):474–80.
7. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP. 1990;24(11):1093–7.
8. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord. 2005;20(11):1502–7.
9. Grosset D, European PD Therapy Compliance Study Group. Therapy adherence issues in Parkinson’s disease. J Neurol Sci. 2010;289:115–8.
10. Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson’s disease: a randomized controlled trial. BMC Neurol. 2007;7:01–6.
11. Pasina L, Brucato AL, Falcone C, Cucchi E, Bresciani A, Sottocorno M, Taddei GC, Casati M, Franchi C, Djade CD, Nobili A. Medication non-adherence among elderly patients newly discharged and receiving polypharmacy. Drugs Aging. 2014;31(4):283–9.
12. Brooks DJ. Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat. 2008;4(1):39–47.
13. Daley DJ, Deane KH, Gray RJ, Worth PF, Clark AB, Sabanathan K, Pfeil M, Myint PK. The use of carer assisted adherence therapy for people with Parkinson’s disease and their carers (CAAT-PARK): study protocol for a randomized controlled trial. Trials. 2011;12:01–12.
14. Schröder S, Martus P, Odin P, Schaefer M. Drug-related problems in Parkinson’s disease: the role of community pharmacists in primary care. Int J Clin Pharm. 2011;33(4):674–82.
15. Poon LH, Lee AJ, Chiao TB, Kang GA, Heath S, Glass GA. Pharmacist’s role in a Parkinson’s disease and movement disorders clinic. Am J Health Syst Pharm. 2012;69(6):518–20.
16. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the patient centered approach to medication management. 3rd ed. New York: McGraw-Hill; 2012.
17. Perlroth D, Marrufo G, Montesinos A, et al. Medication therapy management in chronically ill populations: final report. Blackwell, S.A. 2013. http://innovation.cms.gov/files/reports/mtm_final_report.pdf. Accessed July 24, 2015.
18. Oliveira DR. Atenção Farmacêutica: da filosofia ao gerenciamento da terapia medicamentosa. 1st ed. São Paulo: RCN Editora; 2011.
19. Grimshaw J, Campbell M, Ecclesa M, Steena N. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Fam Pract. 2000;17(sppl1):S11–6.
20. 0 204, de 29 de janeiro de 2007. Regulamenta o financiamento e a transferência dos recursos federais para as ações e os serviços de saúde, na forma de blocos de financiamento, com o respectivo monitoramento e controle. Diário Oficial [da] República Federativa do Brasil, Poder Executivo, Brasília, DF, Jan 2007.
21. Brasil. Portaria no 2.981, de 26 de novembro de 2009. Aprova o Componente Especializado da Assistência Farmacêutica. Diário Oficial [da] República Federativa do Brasil, Brasília, DF, Nov 2009.
22. Mc-Whinney IR. A evolução do método clínico. In: Stewart M, Brown JB, Weston WW, Mc-Whinney IA, Mc William CL, Freeman TR, editors. Medicina centrada na pessoa: transformando o método clínico. 2nd ed. Porto Alegre: Artmed; 2010. p. 35–48.
23. Weed LL. Medical records, patient care, and medical education. Ir J Med Sci. 1964;39(6):271–82.
24. Machuca M, Fernández-Llimós F, Faus MJ. Dáder Method: Manual de Acompanhamento Farmacoterapêutico. GIAF-UGR: Granada; 2003.
25. Papapetropoulos SS. Patient diaries as a clinical endpoint in Parkinson’s disease clinical trials. CNS Neurosci Ther. 2012;18(5):380–7.
26. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.
27. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for clinician. J Psychiatr Res. 1975;12:189–98.
28. Asen KE, Tomson P. Atención Familiar: Guia práctica para los profisionales de la salud. 1st ed. Barcelona: Paidós; 1997.
29. Nascimento LC, Rocha SMM, Hayes VE. Contribuição do Genograma e Ecomapa para o Estudo de Famílias em Enfermagem Pediátrica. Revista Texto and Contexto Enfermagem. 2005;14(2):280–6.
30. Cecagno S, Souza MD, Jardim VMR. Compreendendo o contexto familiar no processo saúde-doença. Acta Scientiarum Health Sci. 2004;26(1):107–12.
31. More CLO. As redes pessoais significativas como instrumento de intervenção interferences psicológica no contexto comunitário. Paidéia. 2005;15(31):287–97.
32. Sluzki CE. A rede social na pratica sistêmica: alternativas terapêuticas. 2nd ed. São Paulo: Casa do Psicólogo; 2003.
33. Zierler-Brown S, Brown TR, Chen D, Blackburn RW. Clinical documentation for patient care: models, concepts, and liability considerations for pharmacists. Am J Health Syst Pharm. 2007;64(17):1851–8.
34. Lana RC, Goulart FRP, Maia T, Prudente C, Cardoso, F. Estudo da confiabilidade do Questionário de Qualidade de Vida na Doença de Parkinson-39 (PDQ-39). In: Anais do VIII Encontro de Extensão da UFMG. Belo Horizonte: UFMG; 2005. p. 01–06.
35. Souza RG, Borges V, Silva SMCA, Ferraz HB. Quality of life scale in Parkinson’s disease PDQ-39—(Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation. Arq Neuropsiquiatr. 2007;65(3):787–91.
36. Martinez-Martin P, Jeukens-Visser M, Lyons KE, et al. Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2011;26(13):2371–80.
37. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–12.
38. Goodman LS, Gilman AG, Brunton LL. As Bases Farmacológicas da Terapêutica. 11th ed. Rio de Janeiro: McGraw Hill; 2006.
39. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.
40. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson’s disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190–9.
41. Barone P, Antonini A, Colosimo C, et al. The priamo study: a multicenter assessment of non-motor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–9.
42. Grosset KA, Bone I, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson’s disease. Mov Disord. 2005;20(11):1397–404.
43. Chemello C, de Souza F, de Souza EP, Farias MR. Pharmaceutical care as a strategy to improve the safety and effectiveness of patients pharmacotherapy at a Pharmacy School: a practical proposal. Braz J Pharm Sci. 2014;50(1):185–93.
44. Navarro-Peternella FM, Marcon SS. Qualidade de vida quality of life de indivíduos com Parkinson e sua relação com tempo de evolução e gravidade da doença. Revista Latino americana de Enfermagem. 2012;20(2):384–91.
45. Ai AL, Carretta H, Beitsch LM, Watson L, Munn J, Mehriary S. Medication therapy management programs: promises and pitfalls. J Manag Care Spec Pharm. 2014;20(12):1162–82.
46. Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, Lohr KN. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(1):76–87.
47. Perseguer-Torregrosa Z, Orozco-Beltrán D, Gil-Guillen VF, et al. Magnitude of pharmacological nonadherence in hypertensive patients taking antihypertensive medication from a community pharmacy in Spain. J Manag Care Spec Pharm. 2014;20(12):1217–25.
48. Gusmão JL, Junior Mion D. Adesão ao tratamento—conceitos. Revista Brasileira de Hipertensão. 2006;13(1):23–5.
49. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. http://www.who.int/chp/knowledge/publications/adherence_report/en/ Accessed July 26, 2015.
50. MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging. 2005;22(3):231–55.
51. De Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–35.
52. Twelves D, Perkins KSM, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord. 2003;18(1):19–31.
53. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–22.
54. Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol. 2002;55(1):25–31.
55. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 2011;8(1):1–58.